George Tidmarsh, a biopharma industry veteran who’s helmed CDER for a little more than three months, resigned yesterday after being placed on administrative leave two days earlier amid a Health and ...
The U.S. FDA once again has a leadership gap at the top of its drug center, which already has been ravaged this year by massive terminations, resignations and retirements of senior leaders. George ...
Tidmarsh, who was named as director of the Center for Drug Evaluation and Research (CDER) in July, told ABC in an interview ...
George Tidmarsh, the FDA's top drug regulator, has been placed on leave after being accused of abusing his regulatory ...
George Tidmarsh has resigned as director of the US Food and Drug Administration’s Center for Drug Evaluation and Research ...
Head of FDA’s drug center George Tidmarsh is the latest member to see his name in headlines. On Friday, October 31, FDA ...
US FDA publishes filing checklists to prevent submission delays: Maryland Saturday, October 25, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FDA) made public filing ...
The Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol ...
The Institute for Safe Medication Practices (ISMP), an ECRI company, has been awarded a contract from the U.S. Food and Drug ...
In a letter to FDA Commissioner Martin Makary, Banks said the agency must "do more to protect the US drug supply," warning that lax oversight could endanger American consumers. He pointed out that ...
Nutriband met with US FDA to obtain feedback on the Chemistry, Manufacturing, and Controls plans for AVERSA™ FENTANYL (abuse deterrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback